Iterum Therapeutics plc
Iterum Therapeutics plc (ITRM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
itrm · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Iterum Therapeutics plc (ITRM) measures how much investors pay for each dollar of the company's trailing earnings. ITRM's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$0.59.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2016 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Iterum Therapeutics plcYou ITRM | $2M | N/A | — | -$0.59 |
 AN2 Therapeutics, Inc. ANTX | $105M | N/A | — | -$1.16 |
 Boundless Bio, Inc. BOLD | $32M | N/A | — | -$2.60 |
 iBio, Inc. IBIO | $27M | N/A | — | -$1.75 |
 Intensity Therapeutics, Inc. INTS | $7M | N/A | — | -$0.86 |
 Klotho Neurosciences, Inc. KLTO | $20M | N/A | — | -$0.32 |
 Pluri Inc. PLUR | $21M | N/A | — | -$3.56 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-1.26 | — | |
2023-12-31 FY2023 | — | $-2.96 | — | |
2022-12-31 FY2022 | — | $-3.63 | — | |
2021-12-31 FY2021 | — | $-8.41 | — | |
2020-12-31 FY2020 | — | $-2.17 | — | |
2019-12-31 FY2019 | — | $-98.22 | — | |
2018-12-31 FY2018 | — | $-122.01 | — | |
2017-12-31 FY2017 | — | $-53.55 | — | |
2016-12-31 FY2016 | — | $-0.96 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Iterum Therapeutics plc (ITRM) measures how much investors pay for each dollar of the company's trailing earnings. ITRM's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$0.59.
Frequently asked questions
ITRM pe ratio · 6 questionsITRM's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.03 and TTM EPS of -$0.59. Data sourced from Financial Modeling Prep via ITRM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Iterum Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08